Vildagil 50 mg (Tablet)
Unit Price: ৳ 18.04 (2 x 10: ৳ 360.80)
Strip Price: ৳ 180.40
Medicine Details
| Category | Details |
|---|---|
| Generic | Vildagliptin |
| Company | Sharif pharmaceuticals ltd |
Indications
- Adjunct to diet and exercise
- Improves glycemic control
- Type 2 diabetes mellitus
- Monotherapy
- Dual combination therapy
- Metformin combination
- Sulphonylurea combination
- Thiazolidinedione combination
- Insulin combination
- Inadequate glycemic control
Pharmacology
- DPP-4 inhibitor
- Incretin hormones
- GLP-1
- GIP
- Insulin synthesis
- Glucagon secretion
- Glucose homeostasis
- Cyclic AMP signaling
- Glucose-dependent manner
Dosage & Administration
- 50 mg or 100 mg daily for monotherapy
- 50 mg twice daily for combination with Metformin or Thiazolidinedione
- 50 mg once daily in the morning for combination with Sulphonylurea
- May be taken with or without a meal
- No dosage adjustment in elderly
- No dosage adjustment in patients with mild renal impairment
- Not recommended in patients under 18 years
Interaction
- No interaction with pioglitazone
- No interaction with metformin
- No interaction with glibenclamide
- No interaction with digoxin
- No interaction with warfarin
- No interaction with amlodipine
- No interaction with ramipril
- No interaction with valsartan
- No interaction with simvastatin
- Potential reduction in glucose-lowering effect with thiazides
- Potential reduction in glucose-lowering effect with corticosteroids
- Potential reduction in glucose-lowering effect with thyroid products
- Potential reduction in glucose-lowering effect with sympathomimetics
Contraindications
- Hypersensitivity to the active substance
- Hypersensitivity to any excipients
- Moderate to severe renal impairment
- Hepatic impairment
- Type 1 diabetes
Side Effects
- Mild and transient adverse reactions
- Rare case of hepatic dysfunction
- No additional safety signals in long-term trials
Pregnancy & Lactation
- Not recommended in pregnancy
- Not recommended during lactation
Precautions & Warnings
- Caution in patients aged 75 years and older
- Monitoring of LFTs prior to initiation
- Three-monthly LFT monitoring in the first year
- Periodic LFT monitoring thereafter
- Discontinuation in case of increased transaminase levels
- Jaundice or signs of liver dysfunction require discontinuation
- Do not reinitiate treatment after withdrawal and LFT normalization
- Use with caution in congestive heart failure patients (NYHA class I-II)
- Avoid use in congestive heart failure patients (NYHA class III-IV)
Therapeutic Class
- Dipeptidyl Peptidase-4 (DPP-4) inhibitor
Storage Conditions
- Store below 30°C
- Keep away from light
- Keep away from moisture
- Keep out of reach of children